Human kallikrein 5: An interesting novel biomarker in ovarian cancer patients that elicits humoral response

International Journal of Gynecological Cancer

Volumn 19, Issue 6, 2009, Pages 1015-1021

  Bandiera, Elisabetta ^a,d   Zanotti, Laura ^a   Bignotti, Eliana ^a   Romani, Chiara ^a   Tassi, Renata ^a   Todeschini, Paola ^a   Tognon, Germana ^a   Ragnoli, Monica ^a   Santin, Alessandro Davide ^b   Gion, Massimo ^c   Pecorelli, Sergio ^a   Ravaggi, Antonella ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Ospedale Civile   (Italy)

^d Laboratorio di Medicina Molecolare BAngelo Nocivelli   (Italy)

Author keywords

ELISA test; Kallikrein related peptidase 5; Ovarian cancer

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; KALLIKREIN 5; KALLIKREIN 5 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CLEAR CELL CARCINOMA; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; MIXED TUMOR; MUCINOUS CARCINOMA; OVARY CARCINOMA; OVARY TUMOR; PELVIS TUMOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; UNDIFFERENTIATED CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEOPLASM; CARCINOMA; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNITY, HUMORAL; IMMUNOASSAY; KALLIKREINS; MIDDLE AGED; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 70349251287     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181ab597f     Document Type: Article

References (20)

1. Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics. 2004;3:355-366.
2. Aletti GD, Gallenberg MM, Cliby WA, et al. Current management strategies for ovarian cancer. Mayo Clin Proc. 2007;82:751-770.
3. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000. CA Cancer J Clin. 2000;50:7-33.
4. Fritsche HA, Bast RC. CA 125 in ovarian cancer: advances and controversy. Clin Chem. 1998;44:1379-1380.
5. Gadducci A, Ferdeghini M, Prontera C, et al. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis. Gynecol Oncol. 1992;44:147-154.
6. Jacobs I, Bast RC Jr. The CA125 tumorYassociated antigen: a review of the literature. Hum Reprod. 1989;4:1-12.
7. Borgono CA, Michael IP, Diamandis EP. Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res. 2004;2:257-280.
8. Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer. 2004;4:876-890.
9. Kim H, Scorilas A, Katsaros D, et al. KLK5 expression is an indicator of poor prognosis in ovarian cancer. Br J Cancer. 2001;84:643-650.
10. Yousef GM, Polymeris ME, Grass L, et al. hK5: a potential novel serum biomarker for breast and ovarian cancer. Cancer Res. 2003;63: 3958-3965. (Pubitemid 36917912)
11. Taylor DD, Gercel-Taylor C. Tumor-reactive immunoglobulins in ovarian cancer: diagnostic and therapeutic significance? Oncol Rep. 1998;5:1519-1524.
12. Stone B, Schummer M, Paley PJ, et al. Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q. Int J Cancer. 2003;104:73-84.
13. Tang R, Ko MC, Wang JY, et al. Humoral response to p53 in human colorectal tumors: a prospective study of 1209 patients. Int J Cancer. 2001;94:859-863.
14. Warnakulasuriya S, Soussi T, Maher R, et al. Expression of p53 in oral squamous cell carcinoma is associated with the presence of IgG and IgA p53 autoantibodies in sera and saliva of the patients. J Pathol. 2000;192:52-57.
15. Beneduce L, Prayer-Galletti T, Giustinian AM, et al. Detection of prostate-specific antigen coupled to immunoglobulin M in prostate cancer patients. Cancer Detect Prev. 2007;31:402-407.
16. Huang CY, Cheng WF, Lee CN, et al. Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor. Anticancer Res. 2006;26:4721-4728.
17. Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108:402-408.
18. Visintin I, Feng Z, Longton G, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res. 2008;14:1065-1072.
19. Michael IP, Sotiropoulou G, Pampalakis G, et al. Biochemical and enzymatic characterization of human kallikrein 5 (hK), a novel serine protease potentially involved in cancer progression. J Biol Chem. 2005;280:14628-14635.
20. Day CH, Fanger GR, Retter MW, et al. Characterization of KLK4 expression and detection of KLK4-specific antibody in prostate cancer patient sera. Oncogene. 2002;21:7114-7120.